Nivagen

Executive Summary

Nivagen is a privately held specialty pharmaceutical company based in Sacramento, California, specializing in the development, manufacturing, and marketing of generic and specialty drugs, including sterile injectables (IV bags, vials, prefilled syringes, cartridges) and 505(b)(2) products. The company also offers 503B compounding services to institutional customers. Founded in 2015, Nivagen operates a state-of-the-art sterile manufacturing facility capable of producing a range of dosage forms with both aseptic and terminal sterilization. The company's focus on complex generics and sterile injectables positions it to address supply shortages and high-demand therapeutic areas. While specific financial details are not public, Nivagen's integrated manufacturing and regulatory expertise provide a competitive edge in the growing generic injectables market. The company is poised to benefit from increased demand for cost-effective pharmaceuticals and compounding services, though limited public information constrains a full assessment.

Upcoming Catalysts (preview)

• TBDFDA approval of a 505(b)(2) new drug application50% success
• TBDExpansion of 503B compounding services into new institutional contracts70% success
• TBDLaunch of a high-value generic injectable product60% success